Hypoxic-Ischemic Encephalopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hypoxic-Ischemic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Hypoxic-ischemic encephalopathy (HIE) is also known as neonatal encephalopathy, perinatal hypoxia, or birth asphyxia. It is a serious birth complication affecting full-term infants less commonly seen in childhood and adulthood. It is caused by loss of oxygen or reduced blood flow to the brain cells. The exact cause of HIE is unknown but brain dysfunction is observed in patients with this condition, causing seizures. Other non-seizure symptoms include cerebral palsy, vision disturbances, learning and attention disorders, and kidney issues. Diagnosis includes physical and laboratory examinations like MRI, EEG, APGAR scores, and abnormal fetal heartbeat. Management of seizures is the primary treatment option; other therapies include and hypothermia (cooling of the body) and symptomatic therapy.
The Hypoxic-Ischemic Encephalopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Hypoxic-Ischemic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoxic-Ischemic Encephalopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hypoxic-Ischemic Encephalopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hypoxic-Ischemic Encephalopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hypoxic-Ischemic Encephalopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypoxic-Ischemic Encephalopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Argenica Therapeutics LtdChiesi Farmaceutici SpA
DeckTherapeutics Inc
Hope Biosciences LLC
Jazz Pharmaceuticals Plc
JCR Pharmaceuticals Co Ltd
Life Sciences Institute
Medinno Inc
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Pharmazz Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Co Ltd
University of Queensland
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hypoxic-Ischemic Encephalopathy reports